Helicobacter pylori eradication therapy for children
Author:
Rysbekov Kairat1ORCID, Abrakhmanova Sagira1, Satybaeva Rashida1, Starosvetova Yekaterina1, Kushugulova Almagul2
Affiliation:
1. Department of Pediatric Diseases with Courses Cardio-Rheumatology and Gastroenterology , 217968 Astana Medical University , Astana , Kazakhstan 2. Laboratory of Human Microbiome and Longevity , National Laboratory Astana , Astana , Kazakhstan
Abstract
Abstract
Objectives
The research aims to investigate the effect of vitamin D supplementation on the efficacy of Helicobacter pylori eradication therapy and to find new drug combinations for the eradication of the bacterium.
Methods
A total of 128 children participated in the research. They were distributed under the following criteria: group A were children who tested positive for H. pylori and were treated with the standard so-called triple therapy including vitamin D; group B were children who tested positive for H. pylori and received the standard triple therapy without including vitamin D in the treatment; and group C were children who tested negative for H. pylori. After endoscopic examination, additional venous blood samples were taken from the children to determine vitamin D levels. A controlled study was carried out 45 days after the initial treatment.
Results
The overall success rate of eradication therapy was 84.1 %. In group A, the success rate of treatment was 93.5 %, contrary to group B, where the success rate was 75 %. Although there was a difference in the percentage of H. pylori eradication therapy in the main group compared to the control group, there was no significant difference in group B. The success rate of eradication is p=0.082.
Conclusions
Following the research results, the addition of vitamin D to the standard triple therapy regimen for H. pylori had no effect. It can therefore be concluded that vitamin D does not significantly increase the efficacy of eradication therapy.
Publisher
Walter de Gruyter GmbH
Reference37 articles.
1. Katelaris, P, Hunt, R, Bazzoli, F, Cohen, H, Fock, KM, Gemilyan, M, et al.. Helicobacter pylori World Gastroenterology Organization global guideline. J Clin Gastroenterol 2023;57:111–26. https://doi.org/10.1097/mcg.0000000000001719. 2. Frost, F, Kacprowski, T, Ruglemann, M, Nabg, C, Franke, A, Zimmermann, K, et al.. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep 2019;9:20100. https://doi.org/10.1038/s41598-019-56631-4. 3. Goh, KL, Chan, WK, Shiota, S, Yamaoka, Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011;16:1–9. https://doi.org/10.1111/j.1523-5378.2011.00874.x. 4. Hooi, JKY, Lai, WY, Ng, WK, Suen, MMY, Underwood, FE, Tanyingoh, D, et al.. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–9. https://doi.org/10.1053/j.gastro.2017.04.022. 5. Benberin, V, Bektayeva, R, Karabayeva, R, Lebedev, A, Akemeyeva, K, Paloheimo, L, et al.. Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. Anticancer Res 2013;33:4596–602.
|
|